1. Introduction {#sec1-jcm-09-00489}
===============

Ischemic stroke (IS), a growing epidemic issue, is the leading cause of long-term disability and the second cause of death worldwide \[[@B1-jcm-09-00489],[@B2-jcm-09-00489],[@B3-jcm-09-00489],[@B4-jcm-09-00489]\]. Thus, it is undoubtedly an extremely important issue and always raises the investigators' interest to find out independently prognostic predictors for patients suffering from acute IS \[[@B5-jcm-09-00489],[@B6-jcm-09-00489],[@B7-jcm-09-00489],[@B8-jcm-09-00489]\]. These predictors are required not only to be simple and unique but also have high sensitivity and specificity \[[@B5-jcm-09-00489],[@B6-jcm-09-00489],[@B7-jcm-09-00489],[@B8-jcm-09-00489]\]. Of these prognostic predictive parameters, circulatory inflammatory biomarkers have been broadly identified and extensively investigated. In fact, plentiful studies have previously demonstrated that circulating levels of inflammatory biomarkers are substantially increased in patients after acute IS \[[@B6-jcm-09-00489],[@B9-jcm-09-00489],[@B10-jcm-09-00489],[@B11-jcm-09-00489],[@B12-jcm-09-00489]\]. Intriguingly, these circulating inflammatory biomarkers were identified as much more increased in severe IS patients than in those with a mild IS \[[@B6-jcm-09-00489],[@B9-jcm-09-00489],[@B10-jcm-09-00489],[@B11-jcm-09-00489],[@B12-jcm-09-00489]\]. Furthermore, a strong correlation between severity of brain damage and systemic inflammatory reactions has also been established \[[@B6-jcm-09-00489],[@B9-jcm-09-00489],[@B10-jcm-09-00489],[@B11-jcm-09-00489],[@B12-jcm-09-00489],[@B13-jcm-09-00489],[@B14-jcm-09-00489],[@B15-jcm-09-00489],[@B16-jcm-09-00489]\].

The relationship between cardiac and neurological functions is closely linked. For example, optimal control of blood pressure is utmost crucial for improvement of clinical outcome among patients after acute IS. This important brain--heart interaction has been further proven by our recent study \[[@B16-jcm-09-00489]\] which has identified that acute IS patients with higher neurological dysfunction had lower left ventricular ejection fractions (LVEF) and higher neutrophil-to-lymphocyte ratios and platelet-to-lymphocyte ratios compared to those with lower National Institute of Health Stroke Scale (NIHSS) ratings. Undoubtedly, cardiovascular disease and cerebrovascular disease share a majority of similar atherosclerotic risk factors, such as hypertension, diabetes mellitus, and hyperlipidemia. Thus, coexistence of cardiovascular disease and cerebrovascular disease is like "two sides of the same coin", i.e., so-called "cerebral--cardiac syndrome (CCS)".

Interleukin (IL)-33, a new member of the IL-1 family of cytokines, promotes Th2 type immune responses by signaling through the suppression of tumorigenesis 2 ligand (ST2L) and IL-1RAcP dimeric receptor complex \[[@B17-jcm-09-00489],[@B18-jcm-09-00489]\]. Additionally, the biological effects of IL-33 are limited by a soluble decoy form of ST2 (i.e., sST2). Abundant data have shown that IL-33/ST2 pathway plays an essential role of chronic inflammatory cardiovascular diseases, atherosclerosis, obesity, cardiac remodeling, and myocardial fibrosis, as well as acts as an independent predictor of mortality in patients with heart failure or myocardial infarction \[[@B17-jcm-09-00489],[@B18-jcm-09-00489],[@B19-jcm-09-00489],[@B20-jcm-09-00489],[@B21-jcm-09-00489],[@B22-jcm-09-00489]\]. However, whether the sST2 can be applied as a novel biomarker for additive risk stratification in patients with acute IS, or even CCS, is currently unclear.

2. Materials and Methods {#sec2-jcm-09-00489}
========================

2.1. Study Design {#sec2dot1-jcm-09-00489}
-----------------

The study design has been clearly described in our recent report \[[@B16-jcm-09-00489]\]. In detail, this was a prospective clinical study performed in a tertiary medical center of southern Taiwan between November 2015 and October 2017. The study protocol was approved by the institutional review boards (IRB number: 104-5222B) of Kaohsiung Chang Gung Memorial Hospital and written informed consent was obtained from all participants prior to enrollment.

2.2. Inclusion and Exclusion Criteria {#sec2dot2-jcm-09-00489}
-------------------------------------

The inclusion and exclusion criteria have been reported in our recent study \[[@B15-jcm-09-00489],[@B16-jcm-09-00489]\]. In detail, eligible patients aged between 45 and 80 years with acute IS regardless of thrombolytic or endovascular therapy were prospectively enrolled into the present study. Acute IS was diagnosed by neurologists based upon detailed clinical assessment, neurological examination, and image modalities which included brain computed tomography or brain magnet resonance imaging.

The exclusion criteria comprised transient ischemic attack, young stroke, cerebellar infarcts, acute hemorrhagic stroke, traumatic brain injury, active infection without treatment, autoimmune diseases, malignancy with life expectancy less than one year, myocardial infarction less than one month, major surgery within three months, advanced liver cirrhosis, and end-stage renal disease on peritoneal dialysis or hemodialysis. Additionally, patients presenting with hemodynamic instability, post cardiopulmonary resuscitation, or indication for immediate surgical intervention were also excluded from the present study.

2.3. Categorization of Stroke into Mild, Moderate, and Severe Neurological Dysfunctions {#sec2dot3-jcm-09-00489}
---------------------------------------------------------------------------------------

The quantification of stroke severity was performed by using National Institute of Health Stroke Scale (NIHSS) \[[@B23-jcm-09-00489]\]. In addition, we evaluated the scales of neurologic deficit with NIHSS (0--42) within 12 h of stroke and global disability severity with the modified Rankin stroke scale (MRS) (0--6). On the basis of the previous reports \[[@B24-jcm-09-00489],[@B25-jcm-09-00489]\], the patients with an NIHSS ≤8 are highly likely to have good clinical outcomes, whereas those with higher NIHSS expressed more severe stroke with poorer prognostic outcomes. Therefore, we categorized the patients into mild IS (i.e., NIHSS ≤8), moderate IS (i.e., NIHSC=9--15), and severe IS (i.e., NIHSS ≥ 16), respectively.

2.4. Patients' Enrollment {#sec2dot4-jcm-09-00489}
-------------------------

The detailed information regarding the sample size calculation has been reported in our recent study \[[@B16-jcm-09-00489]\]. Between November 2015 and October 2017, a total of 110 consecutive subjects who met the inclusion and exclusion criteria were prospectively enrolled into the study. We further excluded 11 cases with hemorrhagic transformation (*n* = 4), life-threatening stress ulcer bleeding (*n* = 3), concomitant heart attack (*n* = 1), complications of aortic dissection (*n* = 1), and another hospital transfer (*n* = 2) after enrollment. Finally, 99 patients were enrolled into the study. All patients were completely surveyed during hospitalization and objectively assessed for in-hospital laboratory and clinical outcomes.

2.5. Flow Cytometric Analysis for Assessment of Circulatory Cells {#sec2dot5-jcm-09-00489}
-----------------------------------------------------------------

Flow cytometric analyses of circulating levels of toll-like receptor (TLR)2+/CD14+ cells, TLR4+/CD14+ cells, Ly6g+/CD14+ cells, and myeloperoxidase (MPO)+/CD14+ cells, four indices of inflammation, were performed by a senior technician who has expertise in flow cytometric analysis and is blinded to the study design, grouping, and treatment strategies. The fluorescence-activated cell sorter machine (FACSCaliburTM system; Beckman Coulter Inc, Brea, CA, USA) was utilized for flow cytometric analysis in the present study.

2.6. ELISA Assessment for Circulating Levels of Proinflammatory Cytokines on Admission {#sec2dot6-jcm-09-00489}
--------------------------------------------------------------------------------------

Circulating levels of interleukin (IL)-33 and sST2, two soluble proinflammatory cytokines, were measured by duplicated determination with a commercially available ELISA method (R&D Systems, Minneapolis, MN, USA). Intra-observer variability of the measurements was also assessed and the mean intra-assay coefficients of variance were all \<4.5%.

2.7. Medications for the Study Patients {#sec2dot7-jcm-09-00489}
---------------------------------------

Aspirin was prescribed for all acute IS patients unless contraindicated. Clopidogrel was prescribed if the patient did not tolerate or was allergized to aspirin. As for those with atrial fibrillation (AF)-related cardioembolic, warfarin or direct oral anticoagulant was prescribed after neurological condition became stable \[[@B26-jcm-09-00489]\]. Other comorbidities or underlying diseases were treated with guideline-direct medications, including statins, oral antidiabetic agents, renin-aldosterone system (RAS) inhibitors, diuretics, calcium channel blockers, and beta blockades.

2.8. Echocardiographic Measurement for LV Systolic Function and Grade of Valvular Regurgitation {#sec2dot8-jcm-09-00489}
-----------------------------------------------------------------------------------------------

All IS subjects in neurology wards or intensive care units received echocardiographic study within 5 days after stroke. Echocardiographic study was performed by a cardiologist who was blinded to the severity of stroke and study allocation. To evaluate cardiac chamber size, LVEF, and grade of mitral regurgitation (MR), conventional echocardiography was performed with standard 2-dimenional (2D) views, M-mode, tissue, and color Doppler assessment. Digital images were collected and data were analyzed according to the standardized echo protocol \[[@B27-jcm-09-00489]\]. Cardioprotective drugs were also adjusted in time according to abnormal findings.

2.9. Definition of Severity of CCS {#sec2dot9-jcm-09-00489}
----------------------------------

After echocardiographic assessment, the severity of CCS was further classified into mild and moderate-severe CCS according to NIHSS score and LVEF. Mild CCS was defined as NIHSS ≤8 and LVEF ≥60%, i.e., mild damage of brain and deterioration of heart function. On the other hand, moderate-severe CCS was defined as NIHSS \>8 and LVEF \<60%, i.e., more predominant brain injury and cardiac dysfunction.

### Statistical Analysis

Independent t and Mann--Whitney U tests were used to compare the difference between groups for continuous variables as appropriate. For discrete or categorical variables, chi-square and Fisher exact tests were applied to detect the proportions between groups. Additionally, Pearson's or Spearman's correlation analysis was adopted to assess the relationship of NIHSS to LVEF. Area under the curve (AUC) of receiver operating characteristic (ROC) curve and Youden's index were further used for calculating cutoff value of mild or moderate-severe CCS. Finally, we performed logistic regression model with univariate and multivariate analyses to identify potential independent predictors of mild or moderate-severe CCS. Statistical analysis was performed using SPSS statistical software for Windows version 22 (SPSS for Windows, version 22; SPSS, IL, USA). A value of *p* \< 0.05 was considered statistically significant.

3. Results {#sec3-jcm-09-00489}
==========

3.1. The Baseline Characteristics of IS Patients in Three Groups ([Table 1](#jcm-09-00489-t001){ref-type="table"}) {#sec3dot1-jcm-09-00489}
------------------------------------------------------------------------------------------------------------------

[Table 1](#jcm-09-00489-t001){ref-type="table"} shows upon admission, the average NIHSS was significantly higher in moderate (group 2) and severe IS (group 3) patients than in mild IS (group 1) counterparts, but it showed no difference between groups 2 and 3. There were no significant differences in terms of age, sex, current smoking, diabetes mellitus, hypertension systolic and diastolic blood pressure, and rates of old myocardial infarction, old stroke, atrial fibrillation, stain, or RAS inhibitor use. Additionally, the white blood cell count, platelet count, and hemoglobin did not differ among the three groups. However, the circulating levels of segment and lymphocyte were significantly lower in group 1 than in groups 2 and 3, but they exhibited no difference between the latter two groups.

The circulating levels of creatinine, total cholesterol, high-density lipoprotein, and low-density lipoprotein cholesterol were similar among the three groups. The triglyceride level was higher in group 1 than in groups 2 and 3, but no difference between groups 2 and 3.

Flow cytometric analysis demonstrated that the circulating level of TLR2+/CD14+ cells was significantly higher in group 3 than in groups 1 and 2, but no difference between groups 1 and 2. On the other hand, the circulating level of TLR4+/CD14+ cells was significantly lower in group 1 than in group 3, but similar between groups 1 and 2 or between groups 2 and 3. The flow cytometric analysis further showed that the circulating level of MPO+/CD14+ cells was significantly higher in group 3 than in groups 1 and 2, and significantly higher in group 2 than in group 1. However, the circulating number of Ly6g+/CD14+ cells did not differ among the three groups.

The ELISA result demonstrated that the circulating level of sST2 was more significantly increased in groups 2 and 3 than in group 1, but no difference between groups 2 and 3. By contrast, the circulating level of IL-33 did not differ among groups. As for echocardiographic results, the LVEF was significantly higher in group 1 than group 3, but it did not differ between groups 1 and 3 or between groups 2 and 3. On the other hand, the mean degree of MR and the in-hospital mortality rate were similar among the three groups.

3.2. Correlation of Circulatory Inflammatory Biomarkers to the Severity of Neurological Dysfunction and Impairment of Heart Function ([Table 2](#jcm-09-00489-t002){ref-type="table"}) {#sec3dot2-jcm-09-00489}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As shown in [Table 2](#jcm-09-00489-t002){ref-type="table"}, to elucidate the correlation of circulatory inflammatory biomarkers to the severity of neurological dysfunction (NIHSS) and to the impairment of heart function (LVEF), the flow cytometric analysis and ELISA method were utilized in the present study. The result demonstrated that the circulating levels of TLR2+/CD14+ cells, TLR4+/CD14+ cells, and MPO+/CD14+ cells via flow cytometric assessment and sST2 level via ELISA assessment were significantly positively correlated to the severity of IS and significantly negatively correlated to cardiac dysfunction. On the other hand, there was no significant relationship of the two inflammatory biomarkers (i.e., Ly6G+/CD14+ cells, IL33) to NIHSS score or LVEF level.

3.3. ROC Curve and Youden's Index for Determining Cutoff Value of the Parameters According to NIHSS, LVEF, and both ([Table 3](#jcm-09-00489-t003){ref-type="table"}) {#sec3dot3-jcm-09-00489}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

[Table 3](#jcm-09-00489-t003){ref-type="table"}A shows downhill change of LVEF, percentage of MPO+/CD14+ cells, and value of sST2 were highly correlated with NIHSS \>8 (AUC \>0.7 and *p* \< 0.001). Similarly, as shown in [Table 3](#jcm-09-00489-t003){ref-type="table"}B, LVEF \<60% was found closely linked to the changes of the NIHSS and the levels of MPO+/CD14+ cells and sST2. Furthermore, [Table 3](#jcm-09-00489-t003){ref-type="table"}C demonstrates the higher correlation was found between mild degree of CCS (i.e., NIHSS ≤8 or LVEF ≥60%) and the levels of MPO+/CD14+ cells and sST-2. The above similar trend was also observed in the moderate-severe degree of CCS ([Table 3](#jcm-09-00489-t003){ref-type="table"}D), suggesting the levels of MPO+/CD14+ cells and sST-2 had the potential to determine the severity of CCS. Of these two parameters, sST2 was identified to have greater discriminating ability for CCS severity, and its cutoff value for the mild and moderate-severe CCS was 13,830 and 17,643, respectively.

3.4. Predictors of the Mild CCS ([Table 4](#jcm-09-00489-t004){ref-type="table"}) and Moderate-Severe CCS ([Table 5](#jcm-09-00489-t005){ref-type="table"}) {#sec3dot4-jcm-09-00489}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

The [Table 4](#jcm-09-00489-t004){ref-type="table"} demonstrates logistic regression analysis was performed to identify independent predictors of mildest CCS (NIHSS ≤8 and LVEF ≥60%). The results demonstrated that age, dyslipidemia, atrial fibrillation, triglyceride, MR (grades 2 to 4), mean TLR2+/CD14+ cells, TLR2+/CD14+ cells \<25%, TLR4+/CD14+ cells \<0.25%, mean MPO+/CD14+cells, MPO+CD14+ cells \<20%, sST2 \<14,000 (pg/mL), and mean sST2 were significantly predictive of mild CCS. After multivariate analysis, we found that sST2 \<14,000 (pg/mL) was the only independent predictor of the mildest CCS.

[Table 5](#jcm-09-00489-t005){ref-type="table"} lists the results of independent factors predictive of the moderate to severe CCS (NIHSS \>8 and LVEF \<60%) using univariate and multivariate analyses. Age, moderate to severe MR, mean TLR2+/CD14+cells (%), TLR2+CD14+ ≥25%, TLR4+/CD14+cells ≥0.25%, mean Ly6G+/CD14+cells (%), MPO+/CD14+cells (%), MPO+/CD14+cells ≥20%, and mean sST-2 and sST2 ≥17,600 (pg/mL) were potentially predictive of moderate-severe CCS. Further multivariate analysis demonstrated that only MPO+/CD14+cells ≥20% and sST2 ≥17,600 (pg/mL) were the independent predictors of moderate-severe CCS. Taken together, the values of sST2 \<14,000 and ≥17,600 (pg/mL) were importantly recognized as the strongest predictors of the mild and moderate-severe CCS, respectively, with a very significant odd ratio and discriminating value.

4. Discussion {#sec4-jcm-09-00489}
=============

The present study designed to investigate whether circulating inflammatory biomarkers act as simple and useful predictors of CCS severity in patients after acute IS reveals several striking clinical information. First, increases in circulatory inflammatory cells (i.e., TLR2+/CD14+, TLR4+/CD14+, MPO+/CD14+) and proinflammatory cytokine (i.e., sST2) were found to be predictive of concomitant neurological and cardiac systolic dysfunction. Second, among all of the inflammation-relevant variables, the percentage of MPO+/CD14+cells (with a cutoff value of ≥20%) and the level of sST2 (with the cutoff value of ≥17,600 (pg/mL)) were the only two independent biomarkers predictive of moderate-severe CCS. Third, of these two biomarkers, sST2 was most strongly predictive of severity of CCS, highlighting that the sST2 with a cutoff value of ≥17,600 (pg/mL) was an utmost important biomarker in our clinical practice to categorize the risk stratification in patients with acute IS.

One important finding in the present study was that as compared with the mild IS patients, the circulating levels of inflammatory cells and proinflammatory cytokines were remarkably increased in severe IS patients. Interestingly, previous studies have established that circulating levels of inflammatory biomarkers are significantly increased in patients after acute IS \[[@B6-jcm-09-00489],[@B9-jcm-09-00489],[@B10-jcm-09-00489],[@B11-jcm-09-00489],[@B12-jcm-09-00489]\]. Of particular concern was that these circulating inflammatory biomarkers were recognized to be much more upregulated in severe IS patients than in those of patients with a mild IS \[[@B6-jcm-09-00489],[@B9-jcm-09-00489],[@B10-jcm-09-00489],[@B11-jcm-09-00489],[@B12-jcm-09-00489]\]. Our finding was, therefore, consistent with those in previous studies \[[@B6-jcm-09-00489],[@B9-jcm-09-00489],[@B10-jcm-09-00489],[@B11-jcm-09-00489],[@B12-jcm-09-00489]\].

Previous study has emphasized that the cardiovascular disease and cerebrovascular disease are "two sides of the same coin", with not only sharing common atherosclerotic risk factors but also being mediated by damage-associated molecular patterns \[[@B7-jcm-09-00489]\]. In the present study, when we took a look at the cerebral--cardiac axis in patients after acute IS, the LVEF, an index of LV function partially affected by moderate to severe MR, was markedly more reduced in severe IS patients than in mild IS patients. Additionally, there was a strong correlation between increased circulatory inflammatory biomarkers and impaired LVEF (refer to [Table 2](#jcm-09-00489-t002){ref-type="table"}). Intriguingly, a link between an increase in inflammatory biomarkers and LV dysfunction/heart failure has been clearly elucidated in settings of IS or brain damage with any etiology \[[@B28-jcm-09-00489],[@B29-jcm-09-00489],[@B30-jcm-09-00489],[@B31-jcm-09-00489]\]. Again, our finding was comparable with the findings of previous studies \[[@B7-jcm-09-00489],[@B28-jcm-09-00489],[@B29-jcm-09-00489],[@B30-jcm-09-00489],[@B31-jcm-09-00489]\] regarding the complex brain--heart interaction.

Undoubtedly, mild grade of IS commonly has the best prognostic outcome among all IS patients. In the present study, we categorized the group of patients with mild CCS (i.e., with NIHSS \<8 and LVEF \>60%) as the mild IS group concomitant with or followed by less cardiac dysfunction. Interestingly, the circulating level of sST2 \<14,000 (pg/mL) was independently predictive of mild CCS, suggesting that circulating sST2 less than 14,000 (pg/mL) checked at the moment of acute IS would be a good prognostic biomarker for the IS or CCS victims.

Previous studies have clearly revealed that the sST2 pathway plays a crucial role in inflammatory cardiovascular diseases, atherosclerosis, and myocardial fibrosis, and is independently predictive of mortality in patients with heart failure or myocardial infarction \[[@B17-jcm-09-00489],[@B18-jcm-09-00489],[@B19-jcm-09-00489],[@B20-jcm-09-00489],[@B21-jcm-09-00489],[@B22-jcm-09-00489]\]. However, there is still lacking data regarding the relation between circulating level of sST2 and the prognostic outcome in patients after acute IS, especially for CCS. In the present study, after multivariate adjustment, we found only two parameters (i.e., MPO+/CD14+cells ≥20%, sST2 ≥17,600 \[pg/mL\]) were delineated as the significantly independent predictors of moderate-severe CCS and only one parameter of sST2 \<14,000 (pg/mL) to be associated with mild CCS, indicating checking sST2 not only predicted the mildest CCS but also the most severe CCS. Therefore, our study established the role of sST2 on discriminating severity of CCS following acute IS.

This study has limitations. First, the sample size was relatively small, especially after allocation into specific groups. Accordingly, some analytical significance would be distorted in the present study. Second, due to an extremely low incidence rate of clinical events, the association between value of sST2 and clinical outcome of CCS, e.g., mortality, was regrettably unable to be analyzed. Third, the study period was also relatively short (i.e., only during hospitalization), and the correlation of increased circulating levels of biomarkers to long-term prognostic outcome was beyond the scope of the present study. Fourth, this study did not perform the correlation between the circulating levels of inflammatory biomarkers and the duration of hospitalization. Thus, we did not provide information regarding who would be hospitalized for longer than the others. Finally, because the treatment was based on guidelines and similar among the IS patients, this study did not provide information with regard to the impact of different treatment strategies on circulatory levels of inflammatory biomarkers and clinical outcome in patients after acute IS.

5. Conclusions {#sec5-jcm-09-00489}
==============

In conclusion, the results of the present study demonstrated that sST2 was a superb biomarker for prediction of CCS severity in patients after acute IS.
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NIHSS

National Institute of Health Stroke Scale
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suppression of tumorigenesis 2 ligand
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MPO

myeloperoxidase
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atrial fibrillation
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###### 

Baseline characteristics of three groups with different severities of acute ischemic stroke (IS).

  Variables                      Mild IS (*n* = 66) \*   Moderate IS (*n* = 14) \*   Severe IS (*n* = 19) \*   *p*-Value
  ------------------------------ ----------------------- --------------------------- ------------------------- -----------
  Average NIHSS                  3.64 ± 2.03 ^a^         12.21 ± 2.33 ^b^            23.11 ± 6.86 ^b^          \<0.001
  Age, year                      62.44 ± 12.08           65.93 ± 8.86                69.89 ± 10.85             0.094
  Sex (male), *n* (%)            36 (54.5%)              9 (64.3%)                   14 (73.7%)                0.302
  Smoker, *n* (%)                25 (37.9%)              5 (35.7%)                   2 (10.5%)                 0.077
  Hypertension, *n* (%)          51 (77.3%)              11 (78.6%)                  17 (89.5%)                0.376
  Diabetes mellitus, *n* (%)     23 (34.8%)              7 (50.0%)                   4 (21.1%)                 0.221
  Dyslipidemia, *n* (%)          35 (53.0%)              2 (14.3%)                   8 (42.1%)                 0.029
  Old MI, *n* (%)                2 (3.0%)                0 (0.0%)                    1 (5.3%)                  1.000
  SBP, mmHg                      165.97 ± 30.35          153.07 ± 28.38              154.37 ± 23.25            0.147
  DBP, mmHg                      91.21 ± 17.40           83.86 ± 18.75               85.05 ± 14.81             0.236
  Old stroke, *n* (%)            11 (16.7%)              3 (21.4%)                   5 (26.3%)                 0.367
  Atrial fibrillation, *n* (%)   6 (9.1%)                0 (0.0%)                    5 (26.3%)                 0.499
  ACEI or ARB, *n* (%)           35 (53.0%)              7 (50.0%)                   5 (26.3%)                 0.119
  Statin, *n* (%)                38 (57.6%)              4 (28.6%)                   11 (57.9%)                0.130
  WBC count, 1000/μL             8.18 ± 2.65             9.11 ± 2.64                 8.56 ± 3.01               0.484
  Segment, %                     63.52 ± 12.35 ^a^       74.55 ± 9.52 ^b^            70.83 ± 14.69 ^b^         0.004
  Lymphocyte, %                  28.39 ± 11.38 ^a^       18.75 ± 7.92 ^b^            18.50 ± 11.57 ^b^         \<0.001
  Hemoglobin, g/dL               14.22 ± 1.79            13.91 ± 2.11                14.33 ± 2.80              0.840
  Platelet count, 1000/μL        214.70 ± 76.24          222.36 ± 44.26              195.74 ± 53.32            0.480
  Creatinine, mg/dL              1.13 ± 0.85             1.24 ± 1.41                 1.37 ± 0.95               0.095
  Total cholesterol, mg/dL       183.42 ± 49.45          193.36 ± 61.61              186.00 ± 37.22            0.777
  HDL, mg/dL                     43.29 ± 14.30           40.29 ± 10.22               47.94 ± 8.56              0.066
  LDL, mg/dL                     100.55 ± 45.79          118.21 ± 59.65              109.00 ± 37.90            0.400
  Triglyceride, mg/dL            141.02 ± 74.35 ^a^      117.50 ± 52.76 ^a,\ b^      95.17 ± 47.05 ^b^         0.041
  TLR2+CD14+, %                  21.14 ± 8.20 ^a^        25.04 ± 8.73 ^a^            36.91 ± 14.30 ^b^         \<0.001
  TLR4+CD14+, %                  0.62 ± 2.94 ^a^         0.50 ± 0.51 ^a,\ b^         0.47 ± 0.53 ^b^           0.003
  Ly6g+CD14+, %                  4.96 ± 5.23             5.99 ± 6.05                 7.00 ± 9.24               0.968
  MPO+CD14+, %                   14.99 ± 11.04 ^a^       23.20 ± 12.85 ^b^           32.67 ± 16.86 ^c^         \<0.001
  Interleukin 33 (pg/mL)         1.92 ± 1.49             1.46 ± 0.71                 3.02 ± 5.21               0.396
  ST2 (pg/mL)                    15855 ± 13056 ^a^       23139 ± 15194 ^b^           35459 ± 21030 ^b^         \<0.001
  2-D echocardiography                                                                                         
  LVEF, %                        67.72 ± 9.40 ^a^        62.55 ± 11.04 ^a,b^         56.59 ± 11.99 ^b^         \<0.001
  MR (2-4), n (%)                15 (24.2%)              3 (23.1%)                   8 (47.1%)                 0.213
  Mortality, n (%)               0 (0.0%)                0 (0.0%)                    2 (10.5%)                 0.109

Data are expressed as means ± standard deviation, or *n* (%). Abbreviation: NIHSS, National Institute of Health Stroke Scale; IS, ischemic stroke; SBP, systolic blood pressure; DBP, diastolic blood pressure, MI, myocardial infarction; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; WBC, white blood cell; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TLR, toll-like receptor; MPO, myeloperoxidase; LVEF, left ventricular ejection fraction; MR, mitral regurgitation. \* Mild IS (group 1), moderate IS (group 2), and severe IS (group 3) was defined as NIHSS ≤8, 9--15, and ≥16, respectively. Letters (a, b, c) indicate significance (at 0.05 level) (by Scheffé's multiple comparison analysis).
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###### 

Correlation of circulatory inflammatory biomarkers to the severity neurological dysfunction and impairment of heart function.

  Variables                     Correlation Coefficient (R)   *p*-Value
  ----------------------------- ----------------------------- -----------
  Severity of stroke                                          
  NIHSS vs. TLR2+/CD14+ cells   0.392                         \<0.001
  NIHSS vs. TLR4+/CD14+ cells   0.237                         0.018
  NIHSS vs. Ly6g+/CD14+ cells   0.009                         0.930
  NIHSS vs. MPO+/CD14+ cells    0.305                         0.003
  NIHSS vs. IL33                0.075                         0.463
  NIHSS vs. sST2                0.511                         \<0.001
  Degree of LV dysfunction                                    
  LVEF vs. TLR2+/CD14+ cells    −0.228                        0.028
  LVEF vs. TLR4+/CD14+ cells    −0.231                        0.025
  LVEF vs. Ly6g+/CD14+ cells    −0.083                        0.425
  LVEF vs. MPO+/CD14+ cells     −0.219                        0.037
  LVEF vs. IL33                 0.026                         0.800
  LVEF vs. sST2                 −0.272₋                       0.008

Abbreviation: TLR, toll-like receptor; IL, interleukin; LVEF, left ventricular ejection fraction; NIHSS, National Institute of Health Stroke Scale; R, Pearson's or Spearman's correlation coefficient; vs., versus.

jcm-09-00489-t003_Table 3

###### 

Area under the curve (AUC) and Youden's index for determining cutoff value of variables based on NIHSS and LVEF.

  Variable                           AUC (*p*-Value)   Youden's Index   Cutoff Value   Sensitivity   Specificity
  ---------------------------------- ----------------- ---------------- -------------- ------------- -------------
  NIHSS \>8 (**A**)                                                                                  
  LVEF (%)                           0.735 (\<0.001)   0.450            34.45          0.741         0.710
  TLR2+/CD14+cells (%)               0.695 (0.004)     0.367            25.5           0.593         0.774
  TLR4+/CD14+cells (%)               0.667 (0.013)     0.312            0.17           0.667         0.645
  Ly6g+CD14+cells (%)                0.513 (0.851)     0.164            4.15           0.519         0.645
  MPO+CD14+cells (%)                 0.735 (\<0.001)   0.370            19.15          0.741         0.629
  IL-33 (pg/mL)                      0.467 (0.627)     0.071            0.5            0.926         0.145
  sST2 (pg/mL)                       0.780 (\<0.001)   0.539            14118          0.926         0.613
  LVEF \<60% (**B**)                                                                                 
  NIHSS                              0.730 (0.001)     0.487            12             0.609         0.879
  MRS                                0.680 (0.011)     0.321            4              0.609         0.712
  TLR2+/CD14+cells (%)               0.654 (0.028)     0.336            25.1           0.609         0.727
  TLR4+/CD14+cells (%)               0.667 (0.018)     0.332            0.17           0.696         0.636
  Ly6g+CD14+cells (%)                0.615 (0.101)     0.289            14.1           0.304         0.985
  MPO+CD14+cells (%)                 0.733 (0.001)     0.432            17.4           0.826         0.606
  IL-33 (pg/mL)                      0.430 (0.320)     0.045            0.33           1.000         0.045
  sST2 (pg/mL)                       0.734 (0.001)     0.474            13,830         0.913         0.561
  NIHSS \>8 and LVEF \<60% (**C**)                                                                   
  TLR2+/CD14+cells (%)               0.739 (0.005)     0.458            25.5           0.714         0.744
  TLR4+/CD14+cells (%)               0.747 (0.003)     0.498            0.17           0.857         0.641
  Ly6g+CD14+cells (%)                0.556 (0.507)     0.247            16.25          0.286         0.962
  MPO+CD14+cells (%)                 0.802 (\<0.001)   0.557            19.55          0.929         0.628
  IL-33 (pg/mL)                      0.469 (0.712)     0.095            0.7            0.929         0.167
  sST2 (pg/mL)                       0.806 (\<0.001)   0.659            17,643         0.929         0.731
  NIHSS ≤8 and LVEF ≥60% (**D**)                                                                     
  MRS                                0.819 (\<0.001)   0.590            4              0.738         0.852
  TLR2+/CD14+cells (%)               0.706 (0.001)     0.393            25             0.619         0.774
  TLR4+/CD14+cells (%)               0.670 (0.004)     0.315            0.17           0.667         0.648
  Ly6g+CD14+cells (%)                0.564 (0.284)     0.214            4              0.548         0.667
  MPO+CD14+cells (%)                 0.748 (\<0.001)   0.385            17.5           0.737         0.648
  IL-33 (pg/mL)                      0.460 (0.504)     0.056            0.35           1.000         0.056
  sST2 (pg/mL)                       0.788 (\<0.001)   0.553            13,830         0.905         0.648

Abbreviation: AUC = area under the receiver operating characteristic curve; NIHSS = National Institute of Health Stroke Scale; MRS = modified Rankins scale; LVEF = left ventricular ejection fraction; NLR = neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TLR = toll-like receptor; CD = cluster of differentiation; Ly6G = lymphocyte antigen 6 complex locus G6D; MPO = myeloperoxidase; IL33 conc. = interleukin 33 concentration; ST2 = suppression of tumorigenesis 2; ST2-IL33R conc. = antibody concentration of ST2-IL33 receptor.
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###### 

Predictors of the mild CCS (NIHSS ≤8 and LVEF ≥60%).

  Severity of CCS                     Univariate Analysis   Multivariate Analysis                                      
  ----------------------------------- --------------------- ----------------------- --------- -------- --------------- ---------
  Age per year                        0.955                 0.919--0.992            0.018                              
  Age ≥65 years                       0.386                 0.166--0.900            0.027                              
  Male sex                            0.895                 0.392--2.045            0.793                              
  Smoker                              2.200                 0.900--5.378            0.084                              
  Systolic blood pressure             1.012                 0.998--1.027            0.100                              
  Diastolic blood pressure            1.013                 0.989--1.038            0.279                              
  Hypertension                        0.476                 0.165--1.370            0.169                              
  Diabetes mellitus                   0.758                 0.321--1.791            0.528                              
  Dyslipidemia                        2.588                 1.112--6.024            0.027                              
  Old myocardial infarction           1.577                 0.138--18.004           0.714                              
  Old stroke                          0.420                 0.147--1.200            0.105                              
  Atrial fibrillation                 0.141                 0.029--0.694            0.016                              
  RAS inhibitor                       1.471                 0.651--3.322            0.354                              
  Statin                              1.375                 0.612--3.088            0.441                              
  Leukocyte                           0.945                 0.815--1.096            0.457                              
  Hemoglobin                          1.136                 0.928--1.390            0.218                              
  Platelet                            1.002                 0.996--1.008            0.563                              
  Creatinine                          0.903                 0.595--1.372            0.633                              
  Total cholesterol                   1.002                 0.994--1.010            0.633                              
  High-density lipoprotein            1.001                 0.971--1.033            0.933                              
  Low-density lipoprotein             0.998                 0.989--1.007            0.655                              
  Triglyceride                        1.010                 1.003--1.018            0.008                              
  Mitral regurgitation (grade 2--4)   0.334                 0.131--0.854            0.022                              
  TLR2+/CD14+cells (%)                0.928                 0.887--0.971            0.001                              
  TLR2+/CD14+cells \<25%              5.000                 2.068--12.089           \<0.001                            
  TLR4+/CD14+cells (%)                1.048                 0.857--1.281            0.650                              
  TLR4+/CD14+cells \<0.25%            3.143                 1.332--7.416            0.009                              
  Ly6G+/CD14+cells (%)                0.937                 0.875--1.004            0.066                              
  MPO+/CD14+cells (%)                 0.926                 0.889--0.964            \<0.001                            
  MPO+/CD14+cells \<20%               3.846                 1.600--9.246            0.003                              
  IL33 (pg/mL)                        0.980                 0.841--1.143            0.801                              
  sST2 (pg/mL)                        1.000                 1.000--1.000            0.002                              
  sST2 \<14,000 (pg/mL)               13.632                4.592--40.469           \<0.001   12.743   3.836--42.328   \<0.001

Abbreviation: CCS = cerebral-cardiac syndrome; NIHSS = National Institute of Health Stroke Scale; LVEF = left ventricular ejection fraction; OR = odds ratio; CI = confidence interval; RAS = renin-angiotensin-system; TLR = toll-like receptor; CD = cluster of differentiation; Ly6G = lymphocyte antigen 6 complex locus G6D; MPO = myeloperoxidase; IL33 = interleukin 33; sST2 = soluble suppression of tumorigenesis 2.

jcm-09-00489-t005_Table 5

###### 

Predictors of the moderate to severe CCS (NIHSS \>8 and LVEF \<60%).

  Severity of CCS                    Univariate Analysis   Multivariate Analysis                                     
  ---------------------------------- --------------------- ----------------------- ------- -------- ---------------- -------
  Age per year                       1.061                 1.004--1.121            0.037                             
  Age ≥65 years                      2.854                 0.848--9.604            0.090                             
  Male sex                           2.217                 0.658--7.476            0.199                             
  Smoker                             0.619                 0.183--2.100            0.442                             
  Systolic blood pressure            0.998                 0.980--1.017            0.850                             
  Diastolic blood pressure           0.985                 0.954--1.018            0.364                             
  hypertension                       0.750                 0.213--2.637            0.654                             
  Diabetes mellitus                  0.556                 0.164--1.879            0.345                             
  Dyslipidemia                       0.631                 0.209--1.901            0.413                             
  Old myocardial infarction          2.600                 0.221--30.531           0.447                             
  Old stroke                         0.230                 0.028--1.859            0.168                             
  Atrial fibrillation                3.476                 0.882--13.705           0.075                             
  RAS inhibitor                      0.302                 0.090--1.015            0.053                             
  Statin                             1.052                 0.357--3.102            0.927                             
  Leukocyte                          0.964                 0.782--1.189            0.733                             
  Hemoglobin                         1.038                 0.992--1.085            0.108                             
  Platelet                           0.995                 0.987--1.003            0.240                             
  Creatinine                         1.474                 0.944--2.302            0.088                             
  Total-cholesterol                  1.003                 0.992--1.014            0.587                             
  High-density lipoprotein           1.018                 0.980--1.059            0.353                             
  Low-density lipoprotein            1.001                 0.989--1.012            0.921                             
  Triglyceride                       0.991                 0.981--1.002            0.097                             
  Mitral regurgitation (grade 2-4)   3.222                 1.058--9.812            0.039                             
  TLR2+/CD14+cells (%)               1.093                 1.036--1.153            0.001                             
  TLR2+CD14+ ≥25%                    6.875                 2.012--23.497           0.002                             
  TLR4+/CD14+cells (%)               1.003                 0.809--1.245            0.977                             
  TLR4+/CD14+cells ≥0.25%            7.909                 2.304--27.152           0.001                             
  Ly6G+/CD14+cells (%)               1.091                 1.012--1.177            0.024                             
  MPO+/CD14+cells (%)                1.088                 1.035--1.143            0.001                             
  MPO+/CD14+cells ≥20%               10.345                2.162--49.490           0.003   6.633    1.244--35.376    0.027
  IL-33 (pg/mL)                      1.127                 0.944--1.346            0.186                             
  sST2 (pg/mL)                       1.000                 1.000--1.000            0.021                             
  sST2 ≥17,600 (pg/mL)               37.174                4.638--297.96           0.001   23.448   2.794--196.801   0.004

Abbreviation: CCS = cerebral-cardiac syndrome; NIHSS = National Institute of Health Stroke Scale; LVEF = left ventricular ejection fraction; OR = odds ratio; CI = confidence interval; RAS = renin-angiotensin-system; TLR = toll-like receptor; CD = cluster of differentiation; Ly6G = lymphocyte antigen 6 complex locus G6D; MPO = myeloperoxidase; IL-33 = interleukin 33; sST2 = soluble suppression of tumorigenesis 2.
